Do Statins Harm Muscle Mitochria? What New Studies Show

Statins prevent cardiovascular events, and for people at high cardiovascular risk their benefits are well established. That is why a new finding in human cardiac tissue deserves careful attention: atorvastatin exposure impaired mitochondrial activity and reduced contractile force in ex vivo heart-muscle preparations. It does not show that statins weaken the hearts of people taking them. It does show that cardiac muscle is not automatically insulated from statins' effects on cellular energy production.

The more clinically relevant evidence still concerns skeletal muscle. Muscle pain, weakness, and fatigue can occur during statin treatment, although severe injury is rare. Recent studies add a plausible biological explanation: high-dose atorvastatin progressively reduced skeletal-muscle oxidative phosphorylation in a small human study, while cell experiments found greater toxicity from atorvastatin than from rosuvastatin. These are mechanistic signals, not a reason to stop a prescribed medication without speaking with the clinician who prescribed it.

Why the cardiac finding is interesting—and preliminary

In a 2024 study of human skeletal and cardiac muscle, researchers collected tissue during open-heart surgery and assessed mitochondrial respiration and contractile behavior in ex vivo preparations. In skeletal muscle, atorvastatin acid and lactone forms inhibited complexes I, II, and III of the electron transport chain and reduced contractile force.

Cardiac muscle showed a different pattern. Complexes I and II activity and fatty-acid oxidation fell, and contractile force also declined. Complex III was not inhibited in cardiac tissue, despite comparable tissue concentrations of statin acid and lactone in cardiac and skeletal homogenates. The difference may reflect tissue-specific biology, but the study did not establish why it occurred.

This is proof-of-concept, not evidence of clinical heart dysfunction in ambulatory statin users. The tissue came from patients undergoing cardiac surgery, and an isolated muscle preparation lacks normal blood flow, hormones, autonomic signaling, and the body's compensatory responses. A reduced force measurement in a laboratory preparation cannot be translated into a percentage change in cardiac output, an arrhythmia risk, or a clinical outcome. Still, it makes the question worth studying rather than assuming the heart is exempt.

High-dose atorvastatin produced a progressive decline in skeletal-muscle respiration

The strongest direct human signal comes from Ryan et al.'s 2024 longitudinal study. Eight sedentary, overweight but otherwise healthy adults took 80 mg of atorvastatin daily—the maximum approved dose—for 56 days. Researchers took vastus lateralis biopsies before treatment and after 14, 28, and 56 days, then measured mitochondrial respiration in permeabilized muscle fibers.

Oxidative phosphorylation capacity declined progressively rather than dropping once and stabilizing. By day 56, complex I-supported respiration, complex II-supported respiration, and total oxidative phosphorylation capacity had each fallen by roughly 30% to 38%. The study also reported 23% to 45% decreases in in vivo indices of muscle oxidative capacity measured with near-infrared spectroscopy.

The authors tested whether the bottleneck might sit at ATP synthase, also called complex V. FCCP uncoupling did not restore oxygen flux to baseline, which points upstream in the electron transport chain. In parallel cell experiments, 10 µM atorvastatin directly inhibited complex I- and complex II-supported respiration; complex IV appeared especially sensitive.

The trajectory matters for people whose exercise tolerance or muscle fatigue worsens over several weeks. This study provides a biologically coherent time course for that experience at 80 mg daily. It does not tell us whether the same decline occurs at 10, 20, or 40 mg daily, how often it occurs, whether it predicts weakness or pain, or what happens after more than eight weeks. With only eight participants, it is a pilot study, not a population estimate.

Statin type may change the cellular risk

Atorvastatin is lipophilic, meaning it more readily enters many tissues than hydrophilic statins such as rosuvastatin. That pharmacologic difference may matter in muscle cells. In a 2025 iPSC-derived muscle-cell study, researchers compared atorvastatin and rosuvastatin at concentrations from 1 to 100 µM in cells derived from six people with familial hypercholesterolemia.

Three donors had previously experienced statin-associated muscle symptoms and three had not. Across cell death, mitochondrial damage, and caspase 3/7 activity, atorvastatin was more cytotoxic than rosuvastatin; the reported differences were statistically significant at p<0.05. Cells from donors with prior muscle symptoms were also more sensitive to atorvastatin than cells from donors without that history. Atorvastatin affected about three times as many genes as rosuvastatin in transcriptomic analyses.

These results support a hypothesis that lipophilicity contributes to muscle toxicity and that some people have greater biological susceptibility. They do not prove that switching from atorvastatin to rosuvastatin will prevent symptoms in a given patient. The experiment included only three donors per subgroup, used iPSC-derived rather than mature muscle fibers, and tested concentrations up to 100 µM, which exceed typical clinical plasma levels.

Population data point in the same direction, but cannot prove cause

A larger real-world signal appears in a 2025 SOMMA cohort analysis of older adults. Statin use was associated with lower skeletal-muscle mitochondrial function than nonuse. The study assessed bioenergetic capacity with ex vivo high-resolution respirometry and in vivo phosphorus magnetic resonance spectroscopy.

Its design limits the conclusion. This was cross-sectional research, so it measured medication use and muscle bioenergetics at one point in time. People prescribed statins generally have higher cardiovascular risk, and cardiovascular disease itself can relate to lower exercise capacity and mitochondrial function. That confounding by indication can create an association even when the medication is not the full cause. The study found a relevant association; it cannot separate drug effect from every difference between users and nonusers.

What exercise can and cannot answer

Aerobic training improves mitochondrial biology in many settings. A 2026 systematic review and meta-analysis of moderate-intensity continuous training found improvements in mitochondrial morphological, enzymatic, and bioenergetic adaptations. In a separate 12-week trial, high-intensity aerobic interval training improved skeletal-muscle mitochondrial structure and respiration in sedentary younger and older adults, whereas resistance training did not increase mitochondrial abundance in that study.

Neither study tested whether exercise prevents or reverses statin-related mitochondrial impairment. Exercise remains sensible for cardiovascular and muscle health, but it is not a proven antidote to statin-associated symptoms. If exercise capacity falls noticeably after a dose change or new prescription, treating harder as a self-experiment may be less useful than documenting symptoms and discussing them with a clinician.

What to do with this evidence

Statins have documented cardiovascular benefits that these mechanistic studies do not erase. The cardiac-tissue result is preliminary, and the progressive human muscle finding came from eight people taking 80 mg of atorvastatin daily. Neither study supports abruptly discontinuing therapy.

But muscle symptoms that worsen after starting or escalating high-dose atorvastatin deserve a specific conversation. Ask about timing, dose, other medications, thyroid status, training load, and whether another statin or dosing approach fits your cardiovascular risk and treatment goals. The cell data make atorvastatin versus rosuvastatin a reasonable topic for that conversation, especially for someone with prior statin-associated muscle symptoms. They do not establish that one choice is universally safer or equally effective at matched clinical doses.

The current evidence supports caution without panic: high-dose atorvastatin can progressively impair skeletal-muscle mitochondrial respiration in a small human study; lipophilic atorvastatin caused more injury than rosuvastatin in a small patient-derived cell model; and ex vivo cardiac tissue shows a signal that needs in vivo testing.

The unanswered study is straightforward in principle: a sufficiently large trial comparing standard-dose atorvastatin, rosuvastatin, and placebo over at least six months, with serial muscle measures, strength, aerobic capacity, symptom reporting, and cardiac imaging. Until then, mitochondrial findings should inform individualized prescribing—not substitute for it.